莫西沙星与加替沙星治疗慢性阻塞性肺疾病急性加重期疗效比较

Moxifloxacin vs.Gatifloxacin for Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Dis-ease

目的：比较莫西沙星与加替沙星治疗慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效及安全性。方法：63例AE—COPD患者随机分成治疗组（30例）与对照组（33例），分别给予莫西沙星和加替沙星治疗7～14d。结果：治疗结束后第7天，治疗组与对照组的临床有效率分别为90．00％、81．82％（P〉0．05），细菌清除率分别为79．17％、72．73％（P〉0．05），不良反应发生率分别为13.33％、18．18％（P〉0．05）。结论：莫西沙星同加替沙星一样，对AECOPD临床疗效确切、安全，可作为AECOPD的经验性抗感染药。

OBJECTIVE： To evaluate the efficacy and safety of moxifloxacin vs.gatifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease（AECOPD） .METHODS;A total of 63 AECOPD patients were enrolled：30 （trial group） were randomly treated with moxifloxacin and other 33（control group） with gatifloxacin all for 7--14days.RESULTS ：On the seventh day after the completion of treatment period,in the trial group vs. control group, the total clinical effective rate was 90,00% vs .81,82% （P ~0.05）, the bacterial eradication rate was 79.17% vs. 72.73% （P〉0.05）,and the incidence of adverse drug reaction was 13.33% vs. 18.18% （P 〉 0.05） .CONCLUSION： Moxifloxacin and gatifloxacin were alike for both have confirmed efficacy and safety for AECOPD and can be used as empirical anti - infective medicine,